EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Field Safety of the Second‐Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs

Faris Jirjis iD, Timothy J Kowalski iD, Robin C Lynn iD, Lindsey Overbey iD, Qi Cao iD, Matthew Stock iD, Inka Kuhlmann iD

Veterinary Dermatology · 2026-12 · 37 (6) · 916-923

DOI: 10.1111/vde.70106 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Veterinary Dermatology, online erschienen am 17.09.2026. Verfasst von Faris Jirjis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck Animal Health, Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Dog Diseases, Janus Kinase 1, Pruritus. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme, Merck Sharp and Dohme K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase (JAK) inhibitors alleviate pruritus and clinical signs of canine atopic dermatitis (cAD).

Objective

To confirm the optimal dosing regimen of atinvicitinib, a second‐generation highly selective inhibitor of JAK1 in dogs. Animals Sixty‐one client‐owned dogs, ≥ 12 months and ≥ 2 kg, with cAD. Materials and Methods In a randomised, masked, placebo‐controlled clinical trial, dogs received atinvicitinib, with food, at 0.8–1.2 mg/kg, once daily for 28 days (q.d. group, n = 21) or 0.4–0.6 mg/kg twice daily for 14 days followed by once daily dosing for 14 days (b.i.d.–q.d. group, n = 21); or placebo b.i.d.–q.d. (control group, n = 19). Owners assessed pruritus (Day [D]0–7, D14, D28) using a Visual Analog Scale (PVAS); veterinary surgeons assessed skin lesions (D0, D28) using the cAD Extent and Severity Index, 4th iteration (CADESI‐04). On D0, D14 and D28, blood and urine samples were collected. Treatment success was defined as a ≥ 50% reduction from baseline PVAS or CADESI‐04 on D28. Proportions of dogs with ≥ 2 PVAS reduction, and reduction in PVAS and/or CADESI‐04 from baseline, also were assessed.

Results

Treatment success was 87.5% for the q.d. group ( p = 0.011) and 73.3% for the b.i.d.–q.d. group ( p = 0.033) (23.1% control group). There was ≥ 2 decrease in PVAS in 80.0% of q.d. dogs. (16.7% controls, p = 0.042). Compared to controls, atinvicitinib‐treated dogs had a significantly greater reduction in PVAS (q.d., p = 0.003, b.i.d.–q.d., p = 0.001) and CADESI‐04 (q.d. group, p = 0.046). Mean results of clinical pathological values remained within reference ranges. Treatment was well‐tolerated. Conclusions and Clinical Relevance Once‐daily atinvicitinib was safe, well‐tolerated and effective at rapidly reducing pruritus and resolving cAD‐associated skin lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicDog DiseasesJanus Kinase 1PruritusAnimalsDogsFemaleMaleDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

Janus kinase 1Janus kinase inhibitorsatopic dermatitisdogsprurituspyrazoles

Substanzen

Janus Kinase 1

Autor:innen und Institutionen

  • Merck Animal Health, Rahway, New Jersey, USA.
  • MSD Animal Health, Boxmeer, the Netherlands.
  • MSD Animal Health, Schwabenheim, Germany.

ORCID-Profile: Faris Jirjis, Timothy J Kowalski, Robin C Lynn, Lindsey Overbey, Qi Cao, Matthew Stock, Inka Kuhlmann

Förderung

  • Merck Sharp and Dohme
  • Merck Sharp and Dohme K.K.

Zitieren

APA

Jirjis, F., Kowalski, T. J., Lynn, R. C., Overbey, L., Cao, Q., Stock, M., & Kuhlmann, I. (2026). Efficacy and Field Safety of the Second‐Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs. Veterinary Dermatology, 37(6), 916-923. https://doi.org/10.1111/vde.70106

Vancouver

Jirjis F, Kowalski TJ, Lynn RC, Overbey L, Cao Q, Stock M, et al. Efficacy and Field Safety of the Second‐Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs. Veterinary Dermatology. 2026;37(6):916-923. doi:10.1111/vde.70106

BibTeX
@article{Jirjis2026,
  author = {Jirjis, Faris and Kowalski, Timothy J and Lynn, Robin C and Overbey, Lindsey and Cao, Qi and Stock, Matthew and Kuhlmann, Inka},
  title = {Efficacy and Field Safety of the Second‐Generation, Highly Selective JAK1 Inhibitor Atinvicitinib for the Treatment of Canine Atopic Dermatitis: A Multicentre, Blinded, Randomised, Placebo‐Controlled Clinical Trial in Client‐Owned Dogs},
  journal = {Veterinary Dermatology},
  year = {2026},
  volume = {37},
  number = {6},
  pages = {916--923},
  doi = {10.1111/vde.70106}
}
Kostenlos starten →